Sales Growth YoY (Last 12 Months): NextCure, Inc. (NXTC)

NextCure, Inc. (NXTC) is scaling antibody production to reduce cost of goods sold, focusing on licensing its developments to major pharmaceutical behemoths. The year-over-year (12-month) relative revenue growth indicator on the GURU.Markets intraday chart reflects sales dynamics, where the value 0.00 serves as the target level. The asset's quotes depend on medical breakthroughs, remaining independent of global economic cycle phases.
NextCure (NXTC) - metric breakdowns and financial figures

Stable bioreactor utilization at NextCure, Inc. (NXTC) ensures the continuous production of experimental antibodies. The YoY commercial revenue growth for LTM measures the percentage change in sales volume over a rolling year, neutralizing seasonality. Through this calculation, the investor separates real operational growth from short-term market fluctuations. Trend analysis allows for an assessment of production capacity efficiency, and this chart objectifies the business's internal potential.